Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros

Base de dados
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Reprod Toxicol ; 120: 108443, 2023 09.
Artigo em Inglês | MEDLINE | ID: mdl-37473931

RESUMO

In a continuing investigation of the potential for reproductive and developmental toxicity of molybdenum (Mo), consequent to the previous published OECD studies [1,2] and as directed by the European Chemicals Agency [3], a supplemental rat GLP-compliant Prenatal Developmental Toxicity (PNDT) study was conducted to investigate higher dose levels of sodium molybdate dihydrate (SMD) in an identical study design (OECD 414)[4] to Murray et al. 2014a [1], at dietary concentrations calculated to provide target Mo levels of 80 and 120 mg/kg bw/day (the maximum-tolerated dose). There was no effect on post-implantation loss, litter size, sex ratio or the incidence of external, visceral or skeletal fetal malformations or variations. Fetal weight was reduced proportionate to maternal dose. Minimal differences observed in the ossification status of some extremities of fetuses from females receiving 120 mg Mo/kg bw/day were confirmed as transient by skeletal examination of PND 21 pups from a further group of females receiving the same dose regime. There was no evidence of copper depletion in serum, placenta or liver. A benchmark dose evaluation using continuous and dichotomous approaches by combining the fetal body weight data from this study and the previous study determined that the BMD05 ranged from 47 to 57 mg Mo/kg bw/day, depending on the modelling approach and the BMDL05 estimates ranged from 37 to 47 mg Mo/kg bw/day. These levels are considered a more statistically robust point of departure for risk assessment for reproductive effects than the established NOAEL of 40 mg Mo/kg bw/day.


Assuntos
Benchmarking , Molibdênio , Gravidez , Feminino , Ratos , Animais , Molibdênio/toxicidade , Ratos Sprague-Dawley , Organização para a Cooperação e Desenvolvimento Econômico , Peso Fetal , Peso Corporal
2.
Eur J Clin Nutr ; 56(11): 1102-7, 2002 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-12428176

RESUMO

OBJECTIVE: The aim of the present study was to determine whether postprandial concentrations of the active component of serine protease coagulation factor VII (VIIa) were lowered by acute boron supplementation in vivo. DESIGN: An acute, randomized, placebo-controlled, double blind, cross-over study. SETTING: Free-living population. SUBJECTS: Fifteen apparently healthy men, aged 45-65 y. INTERVENTIONS: Subjects visited the centre on two occasions, with the study days separated by a minimum of 2 weeks. Following collection of a fasting blood sample, subjects received either placebo or acute bolus of 11.6 mg boron (given as 102.6 mg sodium tetraborate decahydrate) together with a standard fat-rich meal. Blood samples were obtained at 1, 2, 4 and 6 h after the administration of the test meal, during which time subjects were at liberty to consume deionized water only. Blood samples were assayed for concentrations of insulin, glucose, lipids and boron. Measurement of the concentration of activated factor VIIa and of factor VII antigen, and of the activity of coagulation factors VII, IX and X was also carried out. RESULTS: Plasma boron concentrations were significantly higher following consumption of the boron supplement compared with placebo (0.124+/-0.02 vs 0.008+/-0.01 mg/l; P< or =0.001). There was no significant effect of acute boron supplementation on plasma insulin and glucose concentration or on blood lipid or coagulation factor profile. Factor VIIa rose significantly following consumption of the high fat meal (1.05+/-0.07 vs 1.26+/-0.07; P< or =0.001), but this increase was not altered by boron supplementation. CONCLUSIONS: Results from this study suggest that acute boron supplementation (at 11.6 mg boron) does not alter the activity of factor VIIa following consumption of a high-fat meal. SPONSORSHIP: This work was funded by Borax Europe Ltd.


Assuntos
Boro/sangue , Boro/farmacologia , Gorduras na Dieta/metabolismo , Suplementos Nutricionais , Fator VIIa/metabolismo , Idoso , Glicemia/análise , Boro/administração & dosagem , Estudos Cross-Over , Gorduras na Dieta/administração & dosagem , Fator VIIa/efeitos dos fármacos , Jejum , Humanos , Insulina/sangue , Lipídeos/sangue , Masculino , Pessoa de Meia-Idade , Período Pós-Prandial
3.
Xenobiotica ; 18(6): 649-56, 1988 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-3420943

RESUMO

1. The addition of 9000 g supernatant of rat liver homogenate (S9) or rat liver microsomal fractions to a cytotoxicity test system using BCL-D1 cells has been investigated. 2. The choice of culture medium influenced the intrinsic cytotoxicity of the metabolising system to the BCL-D1 cells. Use of Ham's F10 nutrient mixture resulted in greater cytotoxicity compared with several other media. 3. Microsomal fractions provided greater cytochrome P-450 dependent activation of cyclophosphamide and were less cytotoxic than S9. 4. Direct-acting toxic compounds, such as p-aminophenol, were less toxic in the presence of a metabolising system. This was due to protein-binding rather than enzymic detoxification.


Assuntos
Sobrevivência Celular/efeitos dos fármacos , Fígado/metabolismo , Microssomos Hepáticos/metabolismo , Acroleína/metabolismo , Acroleína/farmacologia , Aminofenóis/metabolismo , Aminofenóis/farmacologia , Animais , Biotransformação , Linhagem Celular , Cloromercurobenzoatos/metabolismo , Cloromercurobenzoatos/farmacologia , Clorpromazina/metabolismo , Clorpromazina/farmacologia , Meios de Cultura , Ciclofosfamida/metabolismo , Ciclofosfamida/farmacologia , Avaliação Pré-Clínica de Medicamentos/métodos , Cinética , Masculino , Ratos , Ratos Endogâmicos , Ácido p-Cloromercurobenzoico
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA